Navigation Links
Endo Pharmaceuticals and Alexza Pharmaceuticals Conclude Research Collaboration
Date:1/29/2009

CHADDS FORD, Pa., Jan. 29 /PRNewswire-FirstCall/ -- Endo Pharmaceuticals (Nasdaq: ENDP) announced today that by mutual agreement it has concluded its research collaboration with Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA) to develop an inhaled fentanyl product for the treatment of breakthrough pain using Alexza's Staccato(R) inhalation technology. The product, Staccato(R) fentanyl (AZ-003/EN-3284), has completed Phase I clinical testing and will be returned to Alexza. In 2007, Endo licensed exclusive rights to develop and commercialize AZ-003 in North America.

Ivan Gergel, M.D., Endo's executive vice president of research and development, stated: "As a result of our ongoing strategic review initiated last year, we have terminated certain research and development programs. We have enjoyed working with Alexza and wish them success with their drug development programs. In the meantime, we remain committed to building our pipeline by pursuing programs at all phases of development, including potential products arising from our virtual discovery program."

About Endo

Endo Pharmaceuticals is a specialty pharmaceutical company engaged in the research, development, sale and marketing of branded and generic prescription pharmaceuticals used primarily to treat and manage pain. Its products include LIDODERM(R), a topical patch to relieve the pain of postherpetic neuralgia; PERCOCET(R) and PERCODAN(R) tablets for the relief of moderate-to-moderately severe pain; FROVA(R) tablets for the acute treatment of migraine attacks with or without aura in adults; OPANA(R) tablets for the relief of moderate-to-severe acute pain where the use of an opioid is appropriate; OPANA(R) ER tablets for the relief of moderate-to-severe pain i
'/>"/>

SOURCE Endo Pharmaceuticals
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
3. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
4. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
5. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
6. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
7. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
8. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
9. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
10. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
11. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/14/2014)... 14, 2014  Mylan Inc. (NASDAQ: MYL ) ... with Abbott (NYSE: ABT ... non-U.S. developed markets specialty and branded generics business ("the Assets") ... will receive 105 million shares of the combined company ... $50.20 on Friday, July 11, 2014, representing an approximately 21% ...
(Date:7/13/2014)... July 13, 2014  Eli Lilly and Company ... from its non-clinical study in genetically engineered mice ... the beta-amyloid antibody N3pG and beta-secretase inhibitor BACE ... more effective in removing clumps of amyloid-beta protein ... thought to lead to Alzheimer,s disease (AD) – ...
(Date:7/11/2014)... , July 11, 2014 The consumer ... evolving across industry sectors to better identify winning ... ways to engage with and understand consumers, as ... and make critical purchasing decisions. ... Practices, LLC, one area where organizations can observe ...
Breaking Medicine Technology:Mylan To Acquire Abbott's Non-U.S. Developed Markets Specialty And Branded Generics Business In An All-Stock Transaction 2Mylan To Acquire Abbott's Non-U.S. Developed Markets Specialty And Branded Generics Business In An All-Stock Transaction 3Mylan To Acquire Abbott's Non-U.S. Developed Markets Specialty And Branded Generics Business In An All-Stock Transaction 4Mylan To Acquire Abbott's Non-U.S. Developed Markets Specialty And Branded Generics Business In An All-Stock Transaction 5Mylan To Acquire Abbott's Non-U.S. Developed Markets Specialty And Branded Generics Business In An All-Stock Transaction 6Mylan To Acquire Abbott's Non-U.S. Developed Markets Specialty And Branded Generics Business In An All-Stock Transaction 7Mylan To Acquire Abbott's Non-U.S. Developed Markets Specialty And Branded Generics Business In An All-Stock Transaction 8Mylan To Acquire Abbott's Non-U.S. Developed Markets Specialty And Branded Generics Business In An All-Stock Transaction 9Mylan To Acquire Abbott's Non-U.S. Developed Markets Specialty And Branded Generics Business In An All-Stock Transaction 10Mylan To Acquire Abbott's Non-U.S. Developed Markets Specialty And Branded Generics Business In An All-Stock Transaction 11New Data Shows Combination Therapy is More Effective than Monotherapy in Removing Beta-Amyloid Plaques from the Brains of Mice 2New Data Shows Combination Therapy is More Effective than Monotherapy in Removing Beta-Amyloid Plaques from the Brains of Mice 3New Technologies Transforming Consumer Marketing Research Playbook 2
(Date:7/14/2014)... Institute (BTI) has entered into an agreement with ... to identify novel drug candidates for the detection ... BTI,s capabilities in novel antibody discovery and Roche,s ... opening up the possibility of improved treatment for ... , The collaboration makes use of BTI,s discovery ...
(Date:7/14/2014)... July 14, 2014 Secure Decisions, a ... is partnering with the Software Assurance Marketplace (SWAMP) to ... the software that drives everyday life. , The SWAMP, ... housed in the Morgridge Institute for Research, is funded ... advance software security practices by building a free facility ...
(Date:7/14/2014)... SUNDAY, July 13, 2014 (HealthDay News) -- Along with ... people with Alzheimer,s disease and other types of dementia, ... their quality of life, the researchers said. "These ... variety of benefits for people with dementia and their ... Lerner, of Case Western Reserve University and University Hospitals ...
(Date:7/14/2014)... physically active in middle age appears to help reduce ... dementia, suggest the findings from two new studies. ... various levels, especially in midlife, is beneficial for cognitive ... in an Alzheimer,s Association news release. "These are ... research is needed to determine the extent and nature ...
(Date:7/14/2014)... Amy Norton HealthDay Reporter ... who enjoy mentally stimulating games may have bigger brains and ... The study looked at the connection between playing games such ... adults in their 50s and 60s. Researchers found that ... performed better on tests of memory and other mental functions. ...
Breaking Medicine News(10 mins):Health News:A*STAR partners Roche to develop new cancer therapeutics 2Health News:Madison-based SWAMP, Secure Decisions partner to enhance software security 2Health News:Madison-based SWAMP, Secure Decisions partner to enhance software security 3Health News:Cataract Surgery a Plus for Someone With Dementia, Study Says 2Health News:Staying Active May Help Prevent Dementia 2Health News:Can Games, Puzzles Keep Aging Minds Sharp? 2Health News:Can Games, Puzzles Keep Aging Minds Sharp? 3
... Inc. (R) (HMS) has been closely following ... as it unfolds, especially its impact on ... yesterday on ARRA, even with the up-front investment required ... electronic health record (EHR) technology if they are to ...
... - Predictive medicine company PreMD Inc. (TSX: PMD; PREMF.pk) ... , "Over the last while we have faced significant ... not currently able to continue to finance our clinical ... CEO. "We will be moving to a skeleton staff ...
... Oncology, Inc. ("US Oncology" or "the,Company"), one of the ... million, EBITDA of $52.3 million, Adjusted EBITDA,of $55.2 million, ... of $64.2,million for the three months ended December 31, ... ended December 31, 2008, prior to a first quarter ...
... Coalition Seeks to Increase Public Awareness and Research to ... February 28 To Be Observed Around the World With ... BioMarin Pharmaceutical Inc. (Nasdaq: BMRN ) ... of organizations led by the National Organization for Rare ...
... Manitoba and CINCINNATI, Feb. 26, 2009 Reliance,Products LP ... announce that the U.S.,Environmental Protection Agency (EPA) has approved ... the removal of arsenic, the parasites,Cryptosporidium and Giardia, and ... http://www.newscom.com/cgi-bin/prnh/20090115/CLTH035LOGO-a ) , The EPA ...
... NEW YORK, Feb 26 Our faces are our ... emotions and are connected with three out of the ... But what happens when what you see in the ... Multimedia News Release, go to: http://www.prnewswire.com/mnr/aafprs/35820/ If you ...
Cached Medicine News:Health News:HMS Responds to American Recovery and Reinvestment Act of 2009 2Health News:PreMD Reduces Staffing, Operations - FDA Appeal Still in Process 2Health News:PreMD Reduces Staffing, Operations - FDA Appeal Still in Process 3Health News:US Oncology Reports Fourth Quarter and Yearend 2008 Results 2Health News:US Oncology Reports Fourth Quarter and Yearend 2008 Results 3Health News:US Oncology Reports Fourth Quarter and Yearend 2008 Results 4Health News:US Oncology Reports Fourth Quarter and Yearend 2008 Results 5Health News:US Oncology Reports Fourth Quarter and Yearend 2008 Results 6Health News:US Oncology Reports Fourth Quarter and Yearend 2008 Results 7Health News:US Oncology Reports Fourth Quarter and Yearend 2008 Results 8Health News:US Oncology Reports Fourth Quarter and Yearend 2008 Results 9Health News:US Oncology Reports Fourth Quarter and Yearend 2008 Results 10Health News:US Oncology Reports Fourth Quarter and Yearend 2008 Results 11Health News:US Oncology Reports Fourth Quarter and Yearend 2008 Results 12Health News:US Oncology Reports Fourth Quarter and Yearend 2008 Results 13Health News:US Oncology Reports Fourth Quarter and Yearend 2008 Results 14Health News:US Oncology Reports Fourth Quarter and Yearend 2008 Results 15Health News:US Oncology Reports Fourth Quarter and Yearend 2008 Results 16Health News:US Oncology Reports Fourth Quarter and Yearend 2008 Results 17Health News:US Oncology Reports Fourth Quarter and Yearend 2008 Results 18Health News:US Oncology Reports Fourth Quarter and Yearend 2008 Results 19Health News:US Oncology Reports Fourth Quarter and Yearend 2008 Results 20Health News:US Oncology Reports Fourth Quarter and Yearend 2008 Results 21Health News:US Oncology Reports Fourth Quarter and Yearend 2008 Results 22Health News:US Oncology Reports Fourth Quarter and Yearend 2008 Results 23Health News:BioMarin Supports Observance of Rare Disease Day February 28 2Health News:BioMarin Supports Observance of Rare Disease Day February 28 3Health News:BioMarin Supports Observance of Rare Disease Day February 28 4Health News:Reliance Products and Procter & Gamble Announce EPA Approval of New Claims for PUR Purifier of Water 2Health News:Reliance Products and Procter & Gamble Announce EPA Approval of New Claims for PUR Purifier of Water 3Health News:Video: Facing the Facts - What You Need to Know About Facial Plastic Surgery 2